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Background: Foot-and-mouth disease (FMD) has severe implications for animal farming which leads to considerable
financial losses because of its rapid spread, high morbidity and loss of productivity. For these reasons, the use of
vaccine is often favoured to prevent and control FMD. Selection of the proper vaccine is extremely difficult because of
the antigenic variation within FMDV serotypes. The aim of the current study was to produce a panel of mAbs and use
it for the characterization of new isolates of FMDV serotype O.
Results: A panel of FMDV/O specific mAb was produced. The generated mAbs were then characterized using the
peptide array and mAb resistant mutant selection. Seven out of the nine mAbs reacted with five known antigenic sites,
thus the other two mAbs against non-neutralizing sites were identified. The mAbs were then evaluated by antigenic
ELISA for the detection of forty-six FMDV serotype O isolates representing seven of ten known topotypes. Isolates
ECU/4/10 and HKN/2/11 demonstrated the highest antigenic variation compared to the others. Furthermore, the
panel of mAbs was used in vaccine matching by antigenic profiling ELISA with O1/Manisa as the reference strain.
However, there was no correlation between vaccine matching by antigenic ELISA and the gold standard method, virus
neutralisation test (VNT), for the forty-six FMDV/O isolates. Nine isolates had particularly poor correlation with the
reference vaccine strain as revealed by the low r1 values in VNT. The amino acid sequences of the outer capsid proteins
for these nine isolates were analyzed and compared with the vaccine strain O1/Manisa. The isolate ECU/4/10 displayed
three unique amino acid substitutions around the antigenic sites 1, 3 and 4.
Conclusions: The panel of mAbs is useful to monitor the emergence of antigenically different strains and
determination of relevant antigenic site differences. However, for vaccine matching VNT remains the preferred method
but a combination of VNT, antigenic profiling with a panel of mAbs and genetic sequencing would probably be
more ideal for full characterization of any new outbreak isolates as well as for selection of vaccine strains from FMDV
antigen banks.
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Foot-and-mouth disease (FMD) is a highly infectious and
acute disease that affects cloven-hoofed animals such as
cattle, pigs, goats, sheep and deer. Its rapid spread, high
morbidity and loss of productivity have severe implications
for animal farming which leads to considerable financial
losses. For these reasons, the use of vaccine is often
favoured to prevent and control FMD. Vaccination was
used successfully to help control the FMD outbreak in the
Netherlands in 2001 [1]. Vaccination may be an economic-
ally optimal strategy, although the questions of where, how,
and when to use vaccination for FMD need to be further
addressed [2].
Foot-and-mouth disease virus (FMDV) comes in seven
serotypes (O, A, C, Asia 1, SAT 1, 2 and 3). Among
the seven serotypes of FMDV, O and A are the most
widespread. FMD viruses frequently change at different
antigenic sites. Within the serotypes, there is considerable
antigenic variability [3]. There is no cross-immunity
among the seven serotypes. This is evidenced in animals
that have previously been infected with one serotype, but
remain susceptible to the six other serotypes. Conse-
quently, FMDV-specific antibodies protect only against
homologous, but not heterologous FMD outbreaks. Thus,
the vaccine selected must be highly specific to the strain
involved and matched as closely as possible with the out-
break isolate. It has been indicated that lack of vaccine-
induced protection may involve the use of an inadequately
matched vaccine [4].
A direct relationship has been shown between the level
of serum neutralizing antibody and animal protection [5].
However, selection of the proper vaccine is extremely
difficult because of the antigenic variation within FMDV
serotypes. In general, methods for vaccine strain selec-
tion mainly rely on two in vitro indirect serological
methods: (a) virus neutralisation test (VNT) using
vaccine strain-specific serum pool [6] and (b) an ELISA
using polyclonal antibodies [7]. VNT is more relevant to
in vivo protection than other measures [8] and seems to
produce the most reproducible inter-laboratory results
[9]. Although the neutralisation test has been widely used
for many years, it is time consuming and requires live
virus. In addition, the results are inconsistent because of
(1) different cells and different sera used and (2) different
interpretation of cytopathic effect (CPE) in different
laboratories. ELISA, on the other hand, has advantages
over VNT because it is rapid and no live virus is required.
But the ELISA using polyclonal antibodies is difficult to
standardize.
Sequence analysis can reveal genetic changes of viruses.
Thus it can reveal the emergence of new strains and may
indicate if an outbreak isolate is similar to a vaccine strain
[10]. However, the procedure is complicated and takes
days to complete.Antigenic profiling ELISA using mAbs provides a fast
and more sensitive method for the characterization of field
and vaccine strains [11-15]. A rapid and simple method to
compare antigenic profiles and characterization of new field
isolates has been reported using panels of mAb [16]. How-
ever, antibody binding sites were not well-characterized and
identified in that study. Thus it is impossible to locate
mutations and identify differences among isolates. Mahapatra
et al. [17] reported that they were unable to find a
correlation between the micro neutralization results and
antigenic profiling ELISA using mAbs.
Up until now, the information is limited regarding the
relationship of the r1 values in 2-dimentional (2D)-VNT,
amino acid mutation on capsid protein using genetic se-
quencing and antigenic profiling using a well-characterized
mAb panel. To achieve the goal of simplicity and speed up
the vaccine matching process, a panel of mAbs against
FMDV serotype O was produced. The epitopes recognized
by these mAbs were characterized. This panel of mAbs was
used in antigenic profiling ELISA. Forty-six FMDV/O
isolates were examined using 2D-VNT and antigenic profil-
ing ELISA. Nine isolates lacking close antigenic relationship
with a vaccine strain O1/Manisa in VNT were further
examined using genetic sequence analysis.
Results
Production of monoclonal antibody
A panel of FMDV/O specific mAbs were produced. Four
groups of mice were inoculated separately with serotype
O antigens (Campos, BFS, recombinant Capmpos/Brazil/
58/VP1 or VP2 [18]. Fusions for each group of mice were
performed and allowed for the production of FMDV/O
specific hybridomas. After subcloning, the mAbs were
designated and their isotypes characterized. Nine mAbs
were selected and used in this study (Table 1). The mAbs’
reactivity and specificity against different FMDV serotypes
were examined using FMDV serotype specific double anti-
body sandwich (DAS) ELISAs [18]. The results indicate
that all mAbs are FMDV/O specific without cross reactivity
against FMDV other serotypes (A, C, Asia 1, SAT1, 2,
and 3) and other vesicular disease viruses (Swine vesicular
disease and Vesicular stomatitis). Six of nine mAbs dem-
onstrated virus neutralization activity. Three of them were
non-neutralizing mAbs.
Identification of mAbs’ binding epitope
In order to define the binding epitopes of the mAbs, the
reactivity of the mAbs against recombinant VP1 and VP2
was examined using an indirect ELISA. Four mAbs
reacted with the recombinant proteins (Table 1). The
result showed that three mAbs (F12VP1O-2, F21-48 and
F21-64) reacted with recombinant VP1 protein, while
F11VP2O-2 reacted with recombinant VP2 protein
(Table 1). This confirmed that the epitopes recognized by
Table 1 Characteristics of monoclonal antibodies against FMDV/O and their binding sites
Clone Name Isotype Immunization Ag VNT results Reactivity to recombinant protein Antigenic Sites Binding sites
F1140O2-5 IgG1/k O1 Campos - - - VP3 V73
F11VP2O-2 IgG1/k Rec VP2 - VP2 - VP2 133QK134
F12VP1O-2 IgG1/k Rec VP1 - VP1 Site1b VP1 198EARHKQKIVAPVKQTL213
F21-48 IgG2a/k O1 BFS + VP1 Site1a,5 VP1 148 L
F21-64 IgG2a/k O1 BFS + VP1 Site1a,5 VP1 136YSRNAVPNLRGDLQVL151
F21-34 IgG2b/k O1 BFS + - Near site2 VP2 68D
F21-58 IgG2b/k O1 BFS + - Site2 VP2 77R
F21-41 IgG2b/k O1 BFS + - Site3 VP1 43TP44
F21-18 IgG2a/k O1 BFS + - Near site4 VP3 59G
-: Negative result; +: Positive result.
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proteins were expressed in E. coli. The other mAbs failed
to react with the recombinant proteins suggesting that the
epitope recognized by these mAbs are conformational
which is dependent on the integrity of viral particle
structures. To further locate mAb binding epitopes, 41
peptides representing FMDV/O/VP1 and 42 peptides
corresponding to O/VP2 were synthesized. Reactivity of
the mAbs against peptides was examined using a peptide
ELISA (Figure 1). The mAb F21-64 reacted with peptides
28-29 corresponding to the GH loop of VP1 at amino acids
136-151 (YSRNAVPNLRGDLQVL) which was recognized
as the antigenic site1a. The mAb, F12VP1O-2 reacted with
peptides 40-41 corresponding to the C-terminal residues of
VP1 at amino acids 198-213 (EARHKQKIVAPVKQTL).
This region was identified as the antigenic site1b, despite
the fact that the mAb F12VP1O-2 did not demonstrate virus
neutralization activity. The mAb F21-48 and F11VP2O-2Figure 1 Reactivity of mAbs (F12VP1O-2 and F21-64) with forty-
one O/VP1 overlapping peptides in an indirect ELISA. Forty-one
overlapping peptides and purified FMV/O were coated onto 96-well
plate. The reactivities of the mAbs to the peptides and O1/BFS were
detected with HRP anti-mouse IgG, followed by a substrate.failed to react with any VP1/VP2 peptides, although it
reacted with recombinant proteins.Monoclonal antibody resistant mutant selection
Since conformation-dependent and certain linear epitopes
could not be identified using the peptide array method,
mAb resistant mutant selection was used for the five out
of six neutralizing mAbs. The mAb F21-48 reacted with
recombinant VP1, but failed to react with VP1 peptides.
Thus its binding site was also identified using the mutant
selection. In the mutant selection, the viruses were
allowed to grow in the presence of the mAb with dilutions
100-fold lower than minimum neutralization titer. After
six passages, six mutants were selected and analyzed using
a DAS ELISA. ELISA results showed that the polyclonal
serum reacted with all six parental viruses and selected
mutants, whereas, the mAbs reacted with only parental
viruses, not the matching mutants. The ELISA results
indicated that the mAb binding sites were fully depleted
in those selected mutants.
The five mutant sequences of P1 gene encoding capsid
proteins (VP1, VP2, VP3 and VP4) were compared with
parental O/BFS P1 gene. Mutants are named based on
their matching mAbs. The sequence data revealed that
two selected mutants with the mAbs F21-34 and F21-58
recognized antigenic site 2 in the region of VP2 amino
acid positions about 68 and 77, respectively (Table 1). The
mutant selected with mAbs F21-41 was found to
recognize antigenic site 3 at VP1 amino acid positions
close to 43-44, whereas the mutant selected with F21 -18
recognized near antigenic site 4 at amino acid position
about 59 located in VP3. The mAb F21-48 recognized
antigenic site1a on the GH loop of VP1 at amino acid
position 148 (Table 1). The FMDV/O antigenic sites1a
(site 5), 1b, 2, 3 and 4 identified in this study were similar
as previously published [11,19,20]. The locations of mAb
binding sites are shown in the FMDV 3D structure
(Figure 2).
Figure 2 Localization of antigenic sites in FMDV/O capsid proteins. The O1/ BFS1860 crystal structure (PDB # 1FOD) was manipulated with
Chimera and shown in surface format. a. Locations of previously identified 5 antigenic sites; b. Locations of identified epitopes of anti-FMDV/O mAbs
(summarized in Table 1) showing in red. For VP1 residues 211-213: no corresponding structure in 1FOD (FMDV/O1/ BFS1860 crystal structure).
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against non-neutralizing sites were predicted to bind VP3
at amino acid position around 73, and VP2 region at
amino acid 133-134 respectively, based on the reactivity of
46 isolates in antigenic ELISA and sequence analyses of
P1 region (unpublished data).
Two-dimensional virus neutralization
Antigenic matching is usually estimated indirectly, by
in vitro analysis of the antibody response to vaccination
and by comparing the cross-reactivity of sera collected
from vaccinated animals against the vaccine and field
virus. The 2D-VNT was performed to determine the anti-
genic relationship between the vaccine strains and field
isolates. A 2D-VNT was performed using an antiserum
(21 days post vaccination) raised against FMDV/O1/Ma-
nisa (WRLFMD). A total of forty-six isolates representing
seven of ten known serotype O topotypes were examined
and their r1 values determined as shown in Table 2.
Thirty-seven isolates demonstrated r1 > 0.3, indicating that
these isolates are antigenically similar to the reference
strain, O1/Manisa. Nine viruses (AFG/41/11, ECU/4/10,
ETH/39/09, HKN/2/11, IRN/11/06, KUW/1/11, TAW/12/
98, UAE 9/09, and VIT/32/11) had r1 values of less than0.3 indicates that these strains are not sufficiently related
and cross-protection is less likely to occur, suggesting that
significant antigenic variations exist between reference strain
and these field isolates. Our data are consistent with those
reported by WRLFMD (Table 2).
Antigenic profiling ELISA using the mAb panel
The panel of well characterized mAbs were used in the
antigenic profiling ELISA. To standardize the amount of
virus captured to the plate in the antigenic profiling
ELISA, a serotype independent mAb (F21-42) was used as
a control antibody instead of polyclonal serum. This mAb
demonstrated a consistent binding to all virus isolates
[18], while the polyclonal anti-FMDV/O mouse serum
pool demonstrated poor binding to 6 out of 46 isolates.
The relativities of the mAb panel to the nine isolates
demonstrated poor relationship with the vaccine strain
O/Manisa in 2D-VNT were examined closely. Two isolates
ECU/4/10 and HKN/2/11 showed the highest antigenic
variation among the nine isolates in the antigenic profiling
ELISA (Table 3). Four of the nine mAbs failed to react with
these two isolates (Rx < 0.2). In addition, one mAb demon-
strated low reactivity (Rx < 0.5) to HKN2/11 and two mAbs
demonstrated low reactivity to ECU4/10. It is assumed that
able 2 List of FMDV/O isolates used in the study
MD/O Isolates GenBank accession# Topotypea Antigenic ELISA rb value VNT r1 by NCFAD
c VNT r1 by WRLFMD (reported year)
anisa ME-SA 1.00 1.00 -d
FG/41/11 KJ606977 ME-SA 0.69 0.13 < 0.3 (2011)
HU/39/04 ME-SA 0.45 0.63 -
UL/3/11 ME-SA 0.78 2.63 > 0.3 (2011)
AQ/5/94 ME-SA 0.70 0.52 -
N/11/06 KJ606980 ME-SA 0.41 0.21 -
N/31/10 ME-SA 0.68 0.39 -
N/8/05 ME-SA 0.39 0.63 -
RG/1/06 ME-SA -0.13 1.66 -
RG/2/06 ME-SA -0.28 2.34 -
UW/1/11 KJ606981 ME-SA 0.71 0.16 <0.3 (2011)
GY/8/06 ME-SA 0.81 0.66 -
EP/3/10 ME-SA 0.47 1.17 > 0.3 (2011)
AK/1/10 ME-SA 0.52 0.79 0.46 (2010)
AU/1/09 ME-SA 0.68 0.79 0.74 (2009)
AU/4/05 ME-SA 0.57 0.45 0.78 (2005)
AU/7/08 ME-SA 0.61 0.85 -
AE/2/03 ME-SA 0.76 0.87 -
AE/2/10 ME-SA 0.57 1.32 0.39 (2010)
AE/9/09 KJ606983 ME-SA 0.68 0.12 -
KG/11/01 ME-SA 0.65 1.45 -
KG/13708/01 ME-SA 0.75 1.32 -
KG/14221/01 ME-SA 0.76 1.00 -
IT/32/11 KJ606984 ME-SA 0.34 0.13 <0.3 (2011)
EN/62/09 EA-1 0.66 0.39 -
TH/39/09 KJ606978 EA-3 0.48 0.02 0.16 (2009)
IG/15/09 EA-3 0.30 1.58 > 0.3 (2010)
OM/1/07 EA-3 0.53 0.81 -
UD/3/08 EA-3 0.55 0.79 -
AN/5/09 EA-2 0.70 2.69 > 0.3 (2010)
AM/1/10 EA-2 0.64 1.00 -
FS1860 Euro-SA 0.44 0.32 -
CU/4/10 KC519630 Euro-SA 0.18 0.05 -
KG/685/07 Euro-SA 0.74 2.00 -
KN/1/10 SEA 0.58 0.63 0.5 (2010)
KN/2/11 KJ606979 SEA 0.07 0.10 <0.3 (2011)
AY/1/05 SEA 0.59 0.78 -
YA/1/10 SEA 0.50 1.70 -
YA/11/09 SEA 0.55 1.55 -
KR/4/10 SEA 0.58 1.20 0.57 (2010)
IT/7/06 SEA 0.66 0.81 -
EN/8/06 WA 0.48 0.60 -
AI/15/06 WA 0.44 1.05 -
AW/10/97 CATHAY 0.73 0.35 -















































Table 2 List of FMDV/O isolates used in the study (Continued)
TAW/12/98 KJ606982 CATHAY 0.76 0.19 -
VIT/9/05 CATHAY 0.69 0.50 -
aMiddle East-South Asia (ME-SA); Southeast Asia (SEA); East Africa (EA); Europe-South America (Euro-SA); West Africa (WA).
bCorrelation coefficient between O1Manisa and each isolate.
cNational Centre for Foreign Animal Disease (NCFAD), Canada.
dInformation is not available.
The correlation coefficient (r) for the panel of mAb was calculated between O1/Manisa and each isolate in the antigenic ELISA and the r1 values was determined
in 2D-VNT using an O/Manisa vaccinated serum.
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as well as a non-neutralizing site for each isolate. This
explains why these two isolates demonstrated very low r1
values in 2D-VNT.
The antigenic site 1b identified by mAb F12VP1O-2
showed the highest variation compared with others. Five
out of nine isolates showed littler to no reactivity (Rx < 0.5)
with this mAb. The antigenic sites 2 and 4 demonstrated
higher variations compared with sites1a and 3 based on the
ELISA results. All mAbs reacted with the isolate UAE/9/
2009 indicating that there is no significant change at these
mAb binding sites.
For vaccine matching purpose, reactivity value (Rx)
obtained with each mAb for every field isolate and the
reference strain (O1/Manisa) was used to calculate r values
to normalize the results [16,19], since the O1/Manisa mAb
panel was not available. The r values (Table 2) were used to
determine the strength of the linear association between
the vaccine strain and field isolates. The correlation effi-
ciency between the 2D-VNT and the antigenic ELISA were
also determined based on the 2D-VNT r1 and antigenic
profiling ELISA r values. A poor relationship between the
2D-VNT and the mAb antigenic profiling ELISA results
was observed for the forty-six isolates with a correlation co-
efficient of r = 0.085, p = 0.57.
Sequence analyses
Sequence analysis is used to determine whether an isolate









ECU/4/2010 0.10 1.07 0.49 1.42
HKN/2/2011 1.21 -0.02 1.12 0.25
VIT/32/11 1.22 1.02 0.56 1.51
AFG/41/11 1.13 1.03 0.65 1.17
ETH/39/2009 1.20 1.05 0.39 1.2
UAE/9/2009 1.30 1.03 0.83 1.39
IRN/11/2006 1.07 1.02 0.49 1.13
TAW/12/98 1.58 0.80 0.06 1.57
KUW/1/11 1.26 1.08 0.33 1.30
The values are corrected OD values (RX in M& M) determined in the antigenic ELISA
Values <0.2: no reactivity; <0.5 weak reactivity.encoding capsid proteins of 9 FMDV/O viruses with
r1 < 0.3 were determined. Each contains 2208 nucleotides
with the exception of UAE/9/09 and ECU/4/10, which have
2205 nucleotides. The deduced P1 polyprotein is 736 amino
acids long but the P1 polyprotein of UAE/9/09 and ECU/4/
10, both of which have an amino acid deletion within the
VP1 G-H loop when aligned, is 735 amino acids long.
Identification of antigenic site variation
To better understand antigenic relations between the
vaccine strain and field isolates at amino acid level, the
amino acid sequences of outer capsid proteins were ana-
lyzed. Comparison of the five antigenic sites recognized by
the mAb panel revealed that antigenic sites 2, 3 and 4 are
identical for O1/BFS and O1/Manisa. There are two and
six amino acids variations for antigenic site 1a and 1b rec-
ognized by the mAbs F12VP1O2-1 and F21-64, respectively
for O1/BFS and O1/Manisa. The nine isolates with r1 < 0.3
in 2D-VNT were investigated and compared with the
vaccine strain O1/Manisa. Figure 3 summarized amino acid
alterations observed on the surface of outer capsid proteins
in/near five known antigenic sites. In comparison with a
vaccine strain O1/Manisa, analysis of 5 previously identified
antigenic sites indicated that ECU/4/10 has the highest
antigenic variation in or near antigenic sites. This isolate
displays three unique amino acid substitutions around the
neutralizing sites 1, 3 and 4. There are amino acid deletions
at 139 VP1 GH loop and other amino acid substitutions












0.45 -0.004 0.014 1.76 0.014
0.98 0.05 0.02 1.36 0.05
1.52 0.15 0.04 1.44 1.39
1.20 1.11 1.19 0.28 0.12
1.2 1.15 1.19 1.10 1.05
1.41 0.95 1.36 1.33 0.76
1.10 0.99 1.10 1.08 1.06
1.63 1.55 1.61 0.07 -0.02
1.31 1.25 1.25 0.90 0.73
.
Figure 3 Alignment of partial capsid amino acid sequences of unmatched FMDV/O field isolates and reference strain O1/Manisa. The capsid
proteins of VP1, VP2, and VP3 of the 9 FMDV isolates (shown in Table 3) were aligned by Clustal-W. Only the regions containing 5 previously
determined antigenic sites and unique amino acid substitutions of unmatched isolates and reference strain are shown for clarity. The identical amino
acid residues are indicated by dots. Amino acid deletions are indicated as hyphens. The single letter amino acid code is used. Previously identified
antigenic sites for FMDV/O are indicated with solid horizontal lines or closed circles above the sequences. Amino acid residues with unique substitutions in
the 9 sequences are indicated by open boxes, and the VP1 GH loop residues 130-160 is indicated by a dashed line shown above the sequences.
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0.05) and a very weak correlation coefficient (r = 0.184) in
antigenic profiling ELISA (Table 2). The isolate ETH/39/09
has unique amino acid alterations located around the anti-
genic site 2 and 3. However, the binding of the mAb panel
with ETH/39/09 failed to show any significant reduction at
these locations. But a low binding was observed with the
mAb (F12VP1O-2) located on VP1 C-terminal (Table 3).
All other isolates did not show significant amino acid
alterations compared with the vaccine strain O1/Manisa at
the antigenic sites. However, some amino acid variations
were occurred near the antigenic sites. Within the GH loopof the VP1, it is notably a deletion at VP1 amino acid
position 139 of UAE/9/09. This may explain low r1 values
in 2D-VNT for this strain. Unique amino acid substitutions
for TAW/12/98 (aa 212-A) and KUW/1/11 (aa 205-M)
located at the antigenic site 1b were confirmed by sequence
analysis. Unique amino acid changes were not found within
the outer capsid proteins of the isolate IRN/11/2006.
Discussion
The analysis of antigenic differences is critical for FMD
surveillance and vaccine strain selection. Emergence of
antigenically different strains in FMD outbreak needs to
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using appropriate techniques [21]. As neutralizing anti-
body titers correlate well with protection in animals, the
virus neutralization test has been adopted since 1977 [6]
and is widely used as the reference test system for vaccine
strain selection. Although the 2D-VNT has been consid-
ered the gold standard, significant variation has been
described with the VNT results [6,22]. Mattion [9] indicated
that r1 value estimations using low serum titer become less
precise. Therefore depending on only a single test for
vaccine matching may not be suitable.
To better antigenically monitor new outbreak strains, a
panel of FMDV/O specific mAbs was produced. Seven
mAbs that reacted with the neutralizing sites and two
mAbs that reacted with the non-neutralizing sites were
included in this panel. Four mAbs reacted with recombinant
proteins indicating binding sites of these mAbs were linear.
The binding sites for mAb F12VP1O-2 and F21-64 identi-
fied using peptide ELISA are located on VP1 antigenic site
1b (aa198-213) and 1a (aa136-151). Although the mAb
F12VP1O-2 binding site is located in the antigenic site 1b, it
was unable to neutralize the virus in a VNT. A possible
explanation may be that site 1a (the βG± βH loop) and 1b
(the carboxy terminus) on VP1 together involve antigenicity
and receptor binding [23]. The mAb F12VP1O-2 against
only C-terminal would not be able to completely block
virus attachment, thus demonstrating negative neutralizing
activity.
In general, linear antibody binding epitopes can be lo-
cated using overlapped peptides. Surprisingly, F11VP2O-2
and F21-48 failed to react with any peptides, even though
they reacted with recombinant O/VP 1 and VP2 in an
indirect ELISA. A similar observation has been reported
previously [24]. An explanation is that mAb reactivity with
a continuous epitope not only depends on the amino acid
sequence, but also on a stretch of contiguous residues to
assume the correct conformation [25]. The binding sites
of the other neutralizing mAbs with conformational
epitopes were identified using the mAb resistant mutant
selection method. Though the mAb F21-48 reacted with a
linear epitope, but it was unable to react with any VP1
peptides. The exact binding site was also identified using
the mutant selection method. After the selection in the
presence of high concentrations of mAbs, the neutralizing
mAb resistant mutants were generated and genetically
analysed. The nucleotide mutations causing one signifi-
cant amino acid substitution in protein structures were
determined. The substituted amino acid residue was
considered the antigenic site recognized by the mAbs.
Combining the results obtained from the peptide ELISA
and the mutant selection method, we concluded that the
binding sites of seven mAbs are located on all five previ-
ously identified antigenic sites on FMDV/O involving VP1,
VP2, and VP3 major capsid proteins [11,19,26,27]. It wasconfirmed that these sites were exposed in the 3D model of
protein structure.
Using this well characterized mAb panel, an antigenic
profiling ELISA was developed with a modification from
previously reported ELISA [15]. To correct the amount of
virus trapped by the capture antibody, a serotype inde-
pendent mAb (F21-42) [18] was used to standardize the
ELISA results instead of a polyclonal serum. This mAb
demonstrated a consistent reactivity to all virus isolates,
while the polyclonal anti-FMDV/O mouse serum pool
demonstrated poor binding to some isolates.
The forty-six FMDV/O field isolates were analysed
using the mAb antigenic ELISA. The isolates ECU/4/10
and HKN/2/11demonstrated highest antigenic variation
compared with other isolates. Four of the nine mAbs
failed to react with these two isolates. In addition, one
mAb demonstrated low reactivity to HKN2/11 and two
mAbs demonstrated low reactivity to ECU4/10. It is
assumed that various amino acid alterations occurred in/
near the antibody binding sites. The mutated binding sites
identified by the mAbs for ECU/4/10 are located on the
antigenic sites 1a, 1b, 2, 4 and one on non-neutralizing
site. This result of high antigenic variation is consistent
with previously reported data for the ECU/4/10 isolates
[28]. Viruses circulating in Ecuador during the years
2009–2010 were examined using monoclonal antibody
profiling. The results showed that the viruses lost reactivity
with the four mAbs, three of them with neutralizing
properties. Moreover, results obtained with in vivo challenge
indicated a lack of protection by the vaccine virus (O1/
Campos) [28].
Both the GH loop and the C-terminus of VP1 formed anti-
genic site1 (a, b) are highly exposed regions on virus surface
[23]. It has been indicated that the region of VP1200-273
is important to both antigenicity and receptor binding
of FMDV [19,29-31]. It is involved in cell attachment
because selective removal of these residues resulted in
FMDV particles no longer capable of binding to cells [32].
In this mAb panel, a mAb F12VP1O-2 is able to recognize
this region located on the C-terminal of VP1198-213. Five
out of nine isolates demonstrated weak to no reactivity to
this mAb indicating high variations at this mAb binding
site. Unique amino acid substitutions for TAW/12/98
(aa 212-A) and KUW/1/11 (aa 205-M) were confirmed by
sequence analysis. Those substituted amino acids are
adjacent to the antigenic site 1b (VP1208) and might explain
a low r1 value in 2D-VNT. Likely, this mAb can be used to
monitor whether any mutation occurred in this location.
Correlation coefficients were used to determine the rela-
tionship between the 2D-VNT and the antigenic profiling
ELISA. However, in current study, a poor relationship for
46 isolates between the two tests was observed (r = 0.085,
p = 0.57). In this study, the 2D-VNT was carried out using
a polyclonal serum obtained from the O1/Manisa
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antigenic ELISA was raised against the O1/BSF (O1/Campos)
strain. A previous report indicated that O1/Manisa and
O1/Campos strains are related but they were not a perfect
match by the 2D-VNT (r1 = 0.64/0.62) [33]. The sequence
analysis revealed that the five antigenic sites identified by
the mAb panel in O1/BSF are identical to O1/Manisa in
antigenic sites 2, 3 and 4, but some amino acids changes
were observed in site 1. To obtain better results for
vaccine matching, mAbs raised against each specific
vaccine strain should be used. In practice, this is impossible
because of the large amount of work required for mAb
production and characterization. Alternatively, a pooled of
polyclonal sera from O1/BFS vaccinated animals should be
used in the 2D-VNT to ensure the results are comparable;
however, we were unable to obtain the pooled O1/BFS
vaccinated polyclonal sera. In spite of this, it is unlikely that
the poor correlation between the 2D-VNT and the anti-
genic ELISA is due to the fact that different strains were
used to generate the detecting antibodies in each assay for
two reasons. Firstly, despite the fact that the mAbs were
raised against O1/BFS antigens, the locations of antigenic
sites are common for all serotype O isolates. Thus any
mutations that occur in these sites should be detectable
using the mAb panel. Secondly, the r values of antigenic
profiling ELISA for each isolate were calculated versus the
reference strain (O1/Manisa). Similar finding was reported
by Mahapatra et al., [17] who used the antibodies against
the same strain for mAb antigenic ELISA and VNT; they
also observed a negative correlation between the two tests.
A possible explanation for the poor relationship
between the 2D-VNT and the antigenic ELISA may be
that mAbs are a monovalent antibodies and that a single
mutation occurring in the binding site may cause poor
mAb binding, but may not affect 2D-VNT results by
polyclonal antibodies. Another possibility could be that
in addition to the known sites, other undefined sites
(neutralizing or non-neutralizing) may also be important
in the induction of a protective immune response. This
was supported by the fact that animals with low levels of
neutralizing antibodies could also be protected [34-37]. A
broad repertoire of epitope specificities following vaccin-
ation has been observed in previous studies [38,39]. Also,
Nagendrakumar [33] have reported that the hyperimmune
sera collected from vaccinated animals were unable to
compete with the panel of mAbs used in their study.
Current studies have shown that the antigenic profiling
ELISA is not a substitute for the 2D-VNT in vaccine
matching because of the poor correlation between the two
tests. However, it may still be used as one of the parameters
to measure how field isolates are antigenically related to a
vaccine strain and can provide valuable information on why
a vaccine strain and a field isolate do not match. A good
example is that this approach has been used successfully todefine the epitope mutations of ECU/4/10, although
approximately a 10% sequence difference in VP1 with the
vaccine strain O1/Campos has been reported [28]. Our
finding explained previous finding that why there are no
matching vaccine strains for this isolate.
To improve the current approach, more mAb representa-
tive of each antigenic site and multi panels of well-defined
mAbs against different strains should be included and
used in antigenic ELISAs. More non-neutralizing mAbs
should also be included in the panel since non-neutralizing
antibodies might also contribute to protection [40,41].
These will allow the antigenic ELISA results to be more
compatible with the 2D-VNT.
A powerful screening method for characterising FMD
viruses is the genetic sequencing of the capsid protein.
The genetic sequence can reveal either emergence of new
strains or how similar outbreak isolates are to vaccine
strains. In order to see whether any association exists
between amino acid variation and pattern of r1 value in
2D-VNT, deduced amino acids in the P1 region of 9
isolates with r1 < 0.3 were compared with a vaccine strain
O1/Manisa. The isolate ECU/4/10 and ETH/39/09 display
multiple unique amino acid substitutions and amino acid
depletion on several neutralizing sites. The high sequence
variation of these two isolates explained the low r1 value
for 2D-VNT. All other isolates did not show significant
amino acid alterations compared with the vaccine strain
O1/Manisa on the antigenic sites. However, amino acid
substitutions near antigenic sites were observed. The
changed amino acids near antigenic sites may alter the
structure of outer capsid proteins, rendering antibodies
unable to bind to viruses and preventing reference serum
from neutralizing the viruses.
It has been emphasized that the neutralizing site 1
(VP1140-160) plays a role in the antigenicity of FMDV.
However the residue at position 139 located in the immu-
nodominant region of VP1 (βG-βH loop) is also highly
variable [42]. Amino acid modification at position 139
contributes to serum neutralization resistance in a sero-
type O isolate [43]. In the current study, four isolates,
ETH/39/09, UAE 9/09, TAW/12/98 and VIT/32/11
showed amino acid substitution or deletion at position
139 of VP1 which may explain low r1 values in 2D-VNT.
Similarly, Das et al. [42] noted that three isolates had an
amino acid deletion at position 139 of VP1. This finding
confirmed that this position (VP1139) is antigenically im-
portant. In future sequence analysis, attention should be
paid to this region. Substitutions outside of the antigenic
sites have been shown to play an important role in the
antigenic diversification of FMDV [20,44]. Although one
strain (IRN 11/2006) demonstrated a low r1 (0.21) value in
2D-VNT, no unique amino acid changes were identified
in/near any neutralizing site of the outer capsid proteins.
A possible reason for the low r1 value in 2D-VNT might
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serum pool. It has been suggested that a suitable reference
serum for vaccine matching r1-value experiments should
be a pool or a medium to high titer serum [9]. The r1
value was higher than 0.3 when a different O1/Manisa
vaccinated serum (National Centre for Foreign Animal
Disease, Canadian Food Inspection Agency) was used in
the 2D-VNT.
In comparison to the results of antigenic mAb ELISA
and sequence analysis, multiple mAb binding reduction
(sites 1, 2, 4) in ELISA and several amino acid alterations
in the antigenic sites (sites 1, 3, 4) by sequence analysis
were observed for isolate ECU4/10. No close relationship
was observed between mAb binding and variations in an-
tigenically critical residues for other isolates. Some unique
amino acid changes located in/near antigenic sites were
identified on virus capsid structural proteins by sequence
analysis. On the contrary, the mAb reactivity with those
isolates did not show any significant reduction. The isolate
ETH 39/2009 demonstrated high antigenic variation by
sequence analysis, but only one mAb binding reduction
was detected. One possible explanation may be that
although the amino acid mutation occurred in/near anti-
genic sites, residues are not located in the central part of
epitopes. Thus the binding affinity is not affected signifi-
cantly. Experiments of antibody-antigen binding revealed
that the amino acids in the central part of the epitope–
antibody site make the majority of the contribution to the
antibody–antigen interaction [45]. A second possible ex-
planation may be that despite the amino acid changing, the
protein still folded into the similar 3D capsid structure.
Thus the antibody binding was not reduced.
Conclusions
In the present study, a panel of mAbs against FMDV/O
was produced and characterized. The seven mAbs reacted
with all 5 antigenic sites and the other two mAbs recog-
nized non-neutralizing sites. The panel of mAbs is useful
to monitor and define the emergence of antigenically
different strains giving an approximation of antigenic
differences and to help study the nature of the evolution
of antigenic variation. The antigenic ELISA is the most
rapid test and takes only a short time to obtain results.
Sequence analysis combined with antigenic sites identifi-
cation on capsid regions can reveal existence of amino
acid substitution or deletion of field isolates. Both
methods are valuable tools to assist in the profiling of
outbreak strains in relation to the respective vaccine
strains. However, for vaccine matching VNT remains the
preferred method but a combination of VNT, antigenic
profiling with a panel of mAbs and genetic sequencing
would probably be more ideal for full characterization of
any new outbreak isolates as well as for selection of
vaccine strains from FMDV antigen banks.Material and methods
Preparation of FMDV
All of the FMDV isolates used were obtained from the
World Reference Laboratory for FMD (WRLFMD) at the
Pirbright Institute (Pirbright, UK). FMD viruses were
amplified in Mengeling-Vaughn Porcine Kidney (MVPK)
cells [46]. The cells were cultured in Alpha Modification of
Eagle’s medium (AMEM; WISENT Inc. Canada) supple-
mented with 10% fetal bovine serum (FBS) and 2 mM
L-glutamine. The culture supernatants were clarified by
centrifugation at 8000 rpm for 30 minutes. The procedure
for virus 2-Bromoethylamine Hydrobromide (BEI) inactiva-
tion and purification were performed as previously de-
scribed [18]. The inactivated and purified FMDV was used
for mice inoculation.Production of monoclonal antibodies
Mice immunizations and mAb production were performed
as previously published [18]. Briefly, four groups of female
BALB/C mice were inoculated subcutaneously with each
serotype/O antigen, inactivated and purified Campos, BFS,
and recombinant Capmpos/Brazil/58/VP1 and VP2 [18] in
separate immunizations. The antigens were mixed in an
equal volume of TiterMax Gold (TiterMax USA Inc.,
Norcross, USA). Two to three identical boosts were admin-
istered at four week intervals for each group. Mice were
boosted with the same antigen in phosphate-buffered saline
(PBS) by intravenous injection 3-4 days prior to fusion.
Immunized spleen cells were fused with myeloma cells
(P3X63 Ag8.653, ATCC, Rockville, MD). After 2 weeks,
hybridoma supernatants were screened using a FMDV/O
double antibody sandwich (DAS) ELISA. The positive
clones were subcloned using a limiting dilution method.
Isotyping was performed, using a mouse monoclonal anti-
body isotyping kit (Roche, Indianapolis, IN, USA).Purification of monoclonal antibody
Hybridomas were grown in BD Cell MAb medium (Becton
Dickinson and company, MD, USA) supplemented with
2% FBS. After 7-9 days, the culture supernatants were
harvested. The mAbs were purified from hybridoma culture
supernatants by a HiTrap Protein-G affinity column (GE,
Fairfield, CT) using an AKIA chromatography system
according to manufacturer’s instruction.Peptides
A total of 41 and 43 overlapping peptides representing O1/
BFS VP1 and VP2 (15 amino acids in length, overlapping
each other by 10 amino acids) were synthesized by
Mimotopes (Minneapolis, MN, USA). The peptide ELISA
was performed according to the method described by
Hohlich et al., [47].
Yang et al. Virology Journal 2014, 11:136 Page 11 of 13
http://www.virologyj.com/content/11/1/136Indirect ELISA
Briefly, microtitre plates (Nunc Maxisorb, Roskilde,
Denmark) were coated with purified virus or peptides or re-
combinant FMDV/O1/BFS VP1, VP2 [48]. After blocking,
each hybridoma culture supernatant was added to platea. A
horseradish peroxidase (HRP)-conjugated goat anti-mouse
IgG (1:2000) was added, then O-phenylenediamine dihy-
drochloride (OPD, Sigma-Aldrich, St Lucia, MO, USA) was
used for color development. The optical density (OD) was
measured at 490 nm using an automated plate reader
(Photometer Multiskan Reader, Labsystems, Foster, VA,
USA). Each incubation step was 60 minutes at 37°C with
gentle shaking and followed by washing three times with
washing buffer (PBS with 0.05% Tween 20).
Selection of mAb resistant mutants
FMDV O1/BFS1860 (TCID50 10
7/ml) was mixed with
each purified neutralizing mAbs with dilutions 100-fold
lower than minimum neutralization titer for 30 minutes at
37°C. The virus/mAb mixture and control without mAb
were inoculated onto MVPK cells in T-25 flasks. The
flasks were incubated at 37°C until 100% CPE observed.
The culture supernatants were collected and clarified by
centrifugation at 2000 g for 15 minutes. The 1 ml clarified
supernatant was mixed with the respective mAb and
inoculated onto MVPK cells for the next passage. The
procedure was repeated six times. The mutants selected
were purified by plaque purification.
Two-dimensional virus neutralization test
A two-dimensional neutralisation test (2D-VNT), similar
to that described by Booth et al. [49] was used. Briefly,
two-fold serial dilutions of O1/Manisa vaccinated bovine
serum provided by WRLFMD (our only available serum at
the time) were reacted with 100 to10-3 dilutions of virus
for 1 hour at room temperature. MVPK cells were added
and incubated at 37°C for 3 days. Antibody titres were
calculated from regression data as the log10 reciprocal
antibody dilution required for 50% neutralisation of 100
TCID50 of virus (log10 SN50/100 TCID50). The antigenic
relationship of viruses based on their neutralisation by
antibodies is given by the ratio: ‘r1’ = neutralising antibody
titre of the heterologous virus/neutralising antibody titre
of the homologous virus. Serological relationships be-
tween vaccine strain and field isolates in the range ‘r1’ =
0.3–1.0 are indicative of cross protection, whereas values
< 0.3 indicate dissimilar vaccine strain and test strain [22].
Antigenic profiling ELISA using mAbs
The antigenic profiling ELISA was performed as described
previously [15,29]. Microtitre plates were coated with
polyclonal rabbit anti-FMDV/O1 diluted in 0.06 M
carbonate/bicarbonate buffer, pH 9.6 and incubated
overnight at 4°C. The plates were blocked with a blockingbuffer (5% skim milk in PBS with 0.05% Tween 20) at 37°C
for 1 hour. The FMDV/O isolates diluted in blocking
buffer were added to the plates. The panel of mAbs and a
serotype independent mAb (F21-42) were added at opti-
mal dilutions. After an incubation step, a HRP-goat anti-
mouse IgG (1:2000) was added. Then a substrate OPD
was used for color development. An equal volume of
2.0 M sulfuric acid was added to each well to stop the
color reaction. The OD was measured at 490 nm using an
automated plate reader.
To standardize the reading for the amount of the
different virus attached to each well, the reactivity (RX) of
each mAb with each isolate (X) was calculated based on
the binding (OD) of a control mAb, F21-42 [18] by sub-
tracting the respective blanks (B) using the formula RX =
[(O.D.mAbX-O.D.mAbXB)/(O.D. Control mAb-O.D.Control mAbB) ×100].
The r values between O1/Manisa and each isolate were
calculated based on the reactivity (Rx) obtained with each
mAb as described by Seki [16].
Sequencing FMDV O P1 gene
Genomic RNA was extracted from FMDV using the
Rneasy Mini Kit (Qiagen). Terminal oligonucleotide
primers (Invitrogen) complementary to the L gene (5’-
TTCTGGTGTTTGTCCCGTACGAT-3’) and 2B gene
(5’-GTTGACATGTCCTCCTGCATCTG-3’) for reverse
transcription-PCR and additional ones for internal se-
quencing were chosen from the most conserved sequence
region by alignments of available FMDV/O whole genome
sequences from GenBank. Full-length cDNA copies of the
P1 genes of each virus were synthesized from genomic
RNA by using the terminal primers and SuperScript™ III
reverse transcriptase (Invitrogen). The cDNAs were
amplified by PCR using the Expand™ Long Template PCR
system according to the manufacturer’s instruction
(Roche). PCR products used for DNA sequencing were gel
purified using QIAquick® gel extraction kit according to
the manufacturer’s instruction (Qiagen). DNA sequencing
was performed in both directions by use of an ABI Prism
BigDye Terminator v3.1 Cycle Sequencing Ready Reaction
kit (Applied Biosystems) and an Applied Biosystems
Genetic Analyzer DNA Model 3130X. Sequences obtained
from both directions were assembled and checked for
accuracy with SeqMan® (Lasergene®, Version 9; DNASTAR,
Inc.). Pairwise nucleotide sequence alignments were
performed using the Martinez-NW method [50] and the
Lipman-Pearson method [51] for protein alignments in
MegAlign® (Lasergene).
FMDV 3D structural analyses
Molecular graphics coordinates of the FMDV/O1/BFS1860
crystal structure (PDB # 1FOD) [52] were performed
using the UCSF Chimera package from the Resource
for Biocomputing, Visualization, and Informatics at the
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by NIH (2P41RR001081). The resulting images were
imported into Adobe Photoshop for editing.
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